Zero to Three

Stapokibart efficacy by asthma status in chronic rhinosinusitis with nasal polyps: a post hoc analysis of the CROWNS-2 trial

Background: Asthma is a common comorbidity in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Stapokibart, a novel anti-interleukin-4 receptor alpha monoclonal antibody, demonstrated efficacy and safety in patients with CRSwNP in a phase 3 trial (NCT05436275). Ob...